{"id":408389,"date":"2021-01-05T08:03:33","date_gmt":"2021-01-05T13:03:33","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408389"},"modified":"2021-01-05T08:03:33","modified_gmt":"2021-01-05T13:03:33","slug":"equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","title":{"rendered":"Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">LA JOLLA, Calif., Jan.  05, 2021  (GLOBE NEWSWIRE) &#8212; Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium\u2019s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 11, 2021 at 6:00 am EST.<\/p>\n<p>A webcast of the presentation will be available under the \u201cInvestors\u201d section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t0n8ZI1AFEic8vnWEuH-kGr8L1w0hHWBezS9dmewTTkwTD1lNKU94WM8ERKLrEKzBQm-wc3TfIY3qd5EWGPdQqusrGMYtP72TDQ9WCVdp-g=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/ir.equilliumbio.com\/<\/a> for 30 days.<\/p>\n<p>\n        <strong>About Equillium<\/strong><br \/>\n        <br \/>Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus\/lupus nephritis and uncontrolled asthma.<br \/>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qbHiscn1GRgKrwZrErukDnQNBP4MmfYvszdZO7yy3xdVZU_6g6YYpEHfYvg1w_ChQGJMmLgIMdd9sqbEqBZElpQGppfzQnWqo0Pg1ZxkKLylZmoWroLzJjA7dSag1aAdAagN4U_0M-cAejHRGvU6gS3MUKiVtMlQ5_FpRf8R_TDN4vSQgYY3snrZW-pdTgDtTsLHTtnjCT6536gGI1qJ-3NH1Lo5Oz8zNsdle8uJJUVEs6tJMXe8P0yhrOy_yt758yJF2DOWUzwQBgozOlB1OAYsj2Mt2AN-KTGcjcZnLifqlVik2d5s-rBbaJKy5QJ4Oz_-2Y7S20gEKa0w9MXlX8MeVqx8JokFiXz7dQr5oYGxhip70w98tCSPysLFrdfMJunk28m8rdG57lGZpUUix2IBEAKIVdXv2FlgI9Wct4O0HoqG32J110jhEd74lE6BLfYMl1ecMLkGHb8exaOshkwtavkrxkWtIwJRR4c-Ce2izZy9ce2LZiUKOHFeBaoibUNAWhShOrHtU3bUIlkolYoMBwjb9MlvkUFl9KHWTboIFW1Nnw_8NEu1dUBTsGbSuG28hmcvEIiTbwjEPi2dNDokS61M_44wT8bpALqOFd4VFuao3F9GyPqB06lEjf4-24q807uaa_6etdjy_hK2ZlfPuX48Ur0itgAVeIFfsU51o2qaKENpwgE2rM_gnqYH9uei5c3RXJpv9OviyAAYiw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.equilliumbio.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Michael Moore <br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/>+1-619-302-4431<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gwIuLpiv5jOe6z73iLDSX0x4XQkuuCJUAKB2ScZTE2XTLhKHOQh3r3uAuIkX0IomKegL9S8mVRK6Dh0_YpU_3zqeRzQpZZEdB2UrY3HxpaM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@equilliumbio.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Katherine Carlyle Smith<br \/>Senior Account Associate<br \/>Canale Communications<br \/>+1-805-907-2497 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=arKa1E1wRICLvtICZvkbD2tWIKQN-CG1ugguUg_ZPHxzkWpEG6vAr8i6oy-b7yjmRYWyxRvQCxtsOdcus_QPVztFeBFC6QzmvEDJznwby0ii-ghnfTvJ0OcfgMWtQ4qq\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">katherine.smith@canalecomm.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ4MyMzOTA0MzgzIzIxMjM0MDE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/c6535b35-abbb-463b-a06a-be05ca3076c1\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium\u2019s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 11, 2021 at 6:00 am EST. A webcast of the presentation will be available under the \u201cInvestors\u201d section of the Company\u2019s website at https:\/\/ir.equilliumbio.com\/ for 30 days. About Equillium Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408389","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium\u2019s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 11, 2021 at 6:00 am EST. A webcast of the presentation will be available under the \u201cInvestors\u201d section of the Company\u2019s website at https:\/\/ir.equilliumbio.com\/ for 30 days. About Equillium Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), &hellip; Continue reading &quot;Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T13:03:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ4MyMzOTA0MzgzIzIxMjM0MDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference\",\"datePublished\":\"2021-01-05T13:03:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"},\"wordCount\":176,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQ4MyMzOTA0MzgzIzIxMjM0MDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\",\"name\":\"Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQ4MyMzOTA0MzgzIzIxMjM0MDE=\",\"datePublished\":\"2021-01-05T13:03:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQ4MyMzOTA0MzgzIzIxMjM0MDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQ4MyMzOTA0MzgzIzIxMjM0MDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","og_locale":"en_US","og_type":"article","og_title":"Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","og_description":"LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium\u2019s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 11, 2021 at 6:00 am EST. A webcast of the presentation will be available under the \u201cInvestors\u201d section of the Company\u2019s website at https:\/\/ir.equilliumbio.com\/ for 30 days. About Equillium Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), &hellip; Continue reading \"Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T13:03:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ4MyMzOTA0MzgzIzIxMjM0MDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference","datePublished":"2021-01-05T13:03:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"},"wordCount":176,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ4MyMzOTA0MzgzIzIxMjM0MDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","name":"Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ4MyMzOTA0MzgzIzIxMjM0MDE=","datePublished":"2021-01-05T13:03:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ4MyMzOTA0MzgzIzIxMjM0MDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ4MyMzOTA0MzgzIzIxMjM0MDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408389"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408389\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}